Navigation Links
Celltex autologous stem cell case study published in Stem Cells and Development demonstrates favorable response in pediatric patients
Date:3/13/2017

HOUSTON, March 13, 2017 /PRNewswire/ -- Houston-based biotechnology company Celltex Therapeutics Corporation announces that Stem Cells and Development has published "Autologous Adipose Stem Cell Therapy for Autonomic Nervous System Dysfunction in Two Young Patients." Celltex Chief Scientific Officer, Dr. Jane Young, MD, PhD, is part of the research team who authored the case study focused on two pediatric rheumatoid arthritis patients who are responding favorably to autologous mesenchymal stem cell therapy using stem cells processed by Celltex.

Conducted by researchers in the Texas Medical Center, the peer-reviewed, retrospective case study presents two patients who had clearly defined autoimmune diseases and severe disabilities. Additionally, one pediatric patient had failed standard dysautonomia treatments as well as experienced unsuccessful immunotherapy treatments. The second patient had failed standard treatment for juvenile idiopathic polyarthritis.

"The favorable clinical response in these two young patient warrants further clinical trials using either autologous or allogenic mesenchymal stem cells," the authors wrote in their conclusion.

Dr. Young has extensive academic experience in cell biology, molecular biology, protein science, biochemistry and animal models. Dr. Young is responsible for supervising the production of Celltex's mesenchymal stem cells; evaluating Celltex's stem cells' quality, identity, properties and clinical applications; and she is heavily involved in designing Celltex research, clinical studies and trials, along with physicians in multiple medical centers.

"We are very encouraged by the clinical data obtained in this study, which showed favorable clinical response to Celltex's proprietary stem cell technology in dysautonomia patients," states Dr.Young. "This study is a great representation of Celltex's commitment to leading the United States into the future of regenerative medicine through adult stem cells."

Celltex uses its proprietary technology which isolates, multiplies and banks autologous (one's own) adult mesenchymal stem cells (MSCs) to be used for regenerative therapy for injuries and chronic pain as well as a number of conditions, including vascular, degenerative and autoimmune diseases.

Celltex is registered with the United States Food and Drug Administration as a Human Cell and Tissue Products (HCT/P) establishment that multiplies human cells and cellular products. The company operates in a state-of-the-art laboratory compliant with Current Good Manufacturing Practice (cGMP) standards as recommended by the FDA for the manufacturing of biological products. 

To learn more about Celltex, visit www.celltexbank.com

About Celltex Therapeutics Corporation
Celltex is a Houston-based biotechnology company that is leading the United States into the future of adult stem cell therapy with its proprietary technology. Celltex is committed to expanding the use of adult stem cell therapy by licensed physicians, with the goal of securing the future of regenerative medicine in the United States. For more information about Celltex Therapeutics Corporation, please visit www.celltexbank.com.

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/celltex-autologous-stem-cell-case-study-published-in-stem-cells-and-development-demonstrates-favorable-response-in-pediatric-patients-300422155.html


'/>"/>
SOURCE Celltex Therapeutics Corporation
Copyright©2017 PR Newswire.
All rights reserved


Related biology technology :

1. Functional Regeneration of the Macula with Autologous Stem Cells
2. RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference
3. R-Japan Obtained Autologous Stem Cell Manufacturing License from the Ministry of Health, Labour and Welfare
4. Global Stem Cells Group and Kimera Labs Announce Autologous Stem Cell Research Alliance
5. Study: Brain Imaging After Mild Head Injury/Concussion Can Show Lesions
6. University of Colorado Cancer Center Study Shows that Bitter Melon Juice Prevents Pancreatic Cancer in Mouse Models
7. The Journal of Allergy and Clinical Immunology Publishes Phase 2a Study Results With Cytos Biotechnologys CYT003 for the Treatment of Allergic Asthma
8. Foundation For the NIH Joins NIH In Seeking Proposals to Study Sports-Related Brain Injuries
9. Janssen Announces Data from Simeprevir in Hepatitis C Patients Will Be Presented at The International Liver Congress of the European Association for the Study of the Liver (EASL)
10. Trigemina Receives ISP Approval of Clinical Study Protocol for TI-001 Phase 2 Trial
11. Inflamax Research Chosen to Conduct a Multicenter Environmental Exposure Chamber Phase 3 Study of Ultrashort Grass Allergy Vaccine by Allergy Therapeutics (UK) Ltd.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/9/2019)... ... July 08, 2019 , ... Today, at the BIO ... National Corn Growers Association (NCGA) announced the winners of the Consider Corn Challenge ... or process using field corn to produce biobased materials. , “Corn is a ...
(Date:6/18/2019)... ... ... Personalized Stem Cells, Inc (“PSC”), a human adipose-derived stem cell ... of a person’s own adipose-derived stem cells to treat their osteoarthritis. The first clinical ... IND is the first of several planned clinical trials which will enable qualified PSC-enrolled ...
(Date:6/11/2019)... ... June 11, 2019 , ... ... Carilion Clinic, a national leader in opioid treatment, announced today they are partnering ... , Mytonomy recently deployed its virtual care platform at the Mayo Clinic ...
(Date:5/31/2019)... Redwood City, California (PRWEB) , ... ... ... received allowance of our patent applications from the USPTO providing proprietary interest ... SYSTEM AND METHOD FOR SLEEP DISORDER DIAGNOSIS AND TREATMENT… extends Somnology’s IP ...
Breaking Biology Technology:
(Date:6/14/2019)... ... June 14, 2019 , ... Molecular diagnostics segment is the fastest-growing segment ... in 2019. Major segments that are expected to drive the growth are infectious ... forecasted as segments in Kalorama’s The World Molecular Diagnostics Market, 8th Edition . ...
(Date:6/13/2019)... , ... June 13, 2019 , ... ... the first organization exclusively serving the end-to-end clinical and ancillary supply chain management ... as contract and medical research organizations, today announced it will sponsor a summer ...
(Date:6/11/2019)... ... ... Improved Pharma LLC announces the publication of “Predictive and Accelerated Formulation Design ... published online on April 29th, 2019. The authors are Stephen R. Byrn and ... University. , The article is the most recent addition to a theme dedicated to ...
Breaking Biology News(10 mins):